Key Points
- COO Michael Benkowitz sold 22,500 shares of United Therapeutics on Jan. 12 at an average price of $479.51, a transaction worth about $10.79 million disclosed in an SEC filing.
- Benkowitz has executed a string of large insider sales since November — totaling 225,000 shares across multiple transactions and raising roughly $108.8 million.
- UTHR shares trade around $476.86, while analysts maintain a consensus "Moderate Buy" with an average target of $509.50 and several firms (e.g., UBS) raising price targets.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) COO Michael Benkowitz sold 22,500 shares of United Therapeutics stock in a transaction on Monday, January 12th. The stock was sold at an average price of $479.51, for a total transaction of $10,788,975.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Michael Benkowitz also recently made the following trade(s):
- On Monday, January 5th, Michael Benkowitz sold 7,875 shares of United Therapeutics stock. The shares were sold at an average price of $487.38, for a total transaction of $3,838,117.50.
- On Monday, January 5th, Michael Benkowitz sold 14,625 shares of United Therapeutics stock. The shares were sold at an average price of $487.38, for a total transaction of $7,127,932.50.
- On Monday, December 29th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $502.79, for a total value of $11,312,775.00.
- On Monday, December 22nd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $514.35, for a total value of $11,572,875.00.
- On Monday, December 15th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $496.30, for a total value of $11,166,750.00.
- On Monday, December 8th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $478.58, for a total value of $10,768,050.00.
- On Monday, December 1st, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $479.91, for a total value of $10,797,975.00.
- On Monday, November 24th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $473.66, for a total value of $10,657,350.00.
- On Monday, November 17th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $470.43, for a total transaction of $10,584,675.00.
- On Monday, November 10th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $452.07, for a total transaction of $10,171,575.00.
United Therapeutics Trading Down 1.1%
Shares of UTHR opened at $476.86 on Wednesday. The company's fifty day simple moving average is $485.61 and its 200-day simple moving average is $405.85. The company has a market cap of $20.53 billion, a P/E ratio of 18.07, a P/E/G ratio of 2.51 and a beta of 0.84. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $519.99.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, beating the consensus estimate of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The company had revenue of $799.50 million for the quarter, compared to the consensus estimate of $812.87 million. During the same period in the prior year, the firm posted $6.39 EPS. The firm's revenue was up 6.8% compared to the same quarter last year. Analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of brokerages recently issued reports on UTHR. Weiss Ratings reissued a "buy (b)" rating on shares of United Therapeutics in a research note on Monday, December 29th. UBS Group lifted their target price on United Therapeutics from $600.00 to $645.00 and gave the stock a "buy" rating in a research report on Tuesday, January 6th. HC Wainwright boosted their target price on shares of United Therapeutics from $500.00 to $525.00 and gave the company a "buy" rating in a research note on Thursday, October 30th. Royal Bank Of Canada raised their price target on shares of United Therapeutics from $569.00 to $587.00 and gave the stock an "outperform" rating in a research note on Thursday, October 30th. Finally, Jefferies Financial Group reissued a "buy" rating and issued a $575.00 price objective on shares of United Therapeutics in a research report on Wednesday, November 19th. Eight investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, United Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $509.50.
Check Out Our Latest Research Report on UTHR
Hedge Funds Weigh In On United Therapeutics
Several institutional investors have recently made changes to their positions in UTHR. AQR Capital Management LLC boosted its stake in shares of United Therapeutics by 40.1% during the second quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company's stock valued at $362,876,000 after purchasing an additional 364,713 shares in the last quarter. Invesco Ltd. lifted its holdings in United Therapeutics by 90.2% during the second quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company's stock worth $254,219,000 after buying an additional 419,588 shares during the period. Darwin Global Management Ltd. bought a new stake in United Therapeutics during the 3rd quarter valued at $317,617,000. Assetmark Inc. increased its holdings in shares of United Therapeutics by 38.1% in the 2nd quarter. Assetmark Inc. now owns 715,834 shares of the biotechnology company's stock valued at $205,695,000 after acquiring an additional 197,384 shares during the period. Finally, Norges Bank bought a new position in shares of United Therapeutics in the 2nd quarter worth $136,453,000. Hedge funds and other institutional investors own 94.08% of the company's stock.
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
